Last reviewed · How we verify

ObsEva SA — Portfolio Competitive Intelligence Brief

ObsEva SA pipeline: 0 marketed, 0 filed, 4 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 4 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
OBE2109 OBE2109 phase 3 Selective progesterone receptor modulator (SPRM) Progesterone receptor (PR) Gynecology / Reproductive Health
Add-back Add-back phase 3 Progestin (add-back therapy component) Progesterone receptor Gynecology / Reproductive Health
Placebo to match Add-back Placebo to match Add-back phase 3
Placebo to match OBE2109 Placebo to match OBE2109 phase 3

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Bayer · 1 shared drug class
  2. PregLem SA · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for ObsEva SA:

Cite this brief

Drug Landscape (2026). ObsEva SA — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/obseva-sa. Accessed 2026-05-14.

Related